CytomX Therapeutics, Inc.

CTMXSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1501989

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$101.2M	$53.2M	$37.3M	$57.5M	$59.5M
Research and Development Expense	$77.7M	$111.6M	$114.2M	$131.6M	$103.9M
Operating Expenses	$107.7M	$154.5M	$153.4M	$168.4M	$137.4M
Operating Income (Loss)	-$6.5M	-$101.3M	-$116.0M	-$110.9M	-$77.9M
Interest Expense	—	—	—	—	—
Other Nonoperating Income (Expense)	-$30.0K	$340.0K	-$83.0K	-$135.0K	-$68.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	$3.3M	-$99.3M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$201.8M	$260.9M	$339.4M	$358.7M	$341.3M
Assets, Current	$182.9M	$237.1M	$310.3M	$324.0M	$303.3M
Cash and Cash Equivalents, at Carrying Value	$17.2M	$193.7M	$205.5M	$188.4M	$188.4M
Accounts Receivable, after Allowance for Credit Loss, Current	$3.4M	$36.0M	$790.0K	$798.0K	$13.0K
Liabilities	$249.2M	$346.6M	$339.9M	$308.9M	$290.2M
Liabilities, Current	$155.9M	$152.6M	$77.9M	$100.9M	$85.6M
Long-term Debt, Excluding Current Maturities	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$56.0M	-$110.8M	-$119.0M	-$140.5M	-$75.5M
Net Cash Provided by (Used in) Investing Activities	-$150.7M	$98.3M	$22.5M	$79.7M	$5.9M
Net Cash Provided by (Used in) Financing Activities	$30.2M	$648.0K	$110.2M	$1.6M	$139.6M
Payments to Acquire Property, Plant, and Equipment	$840.0K	$1.7M	$1.6M	$3.5M	$3.8M

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)